Dr. Apelian has previously served as clinical director of infectious disease at Bristol-Myers Squibb, New York-based biopharmaceutical company, and clinical director of hepatology and gastroenterology at Schering Plough, New Jersey-based pharmaceutical company that has since merged with Merck & Co.
He will head the clinical development of Achillion’s hepatitis C treatments.
More Articles on Gastroenterology:
Vision-Sciences Names Howard Zauberman Interim CEO
Dr. Allen Kamrava to Invest, Practice at La Peer Health Systems
Dr. Roger Klein Joins Summit Medical Group
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
